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Background: Of the eight cell surface glycoproteins in the C. albicans Als family, Als3 makes the largest contribution to
adhesion to human cells.
Results:Mutation of the Als3 peptide-binding cavity (PBC) results in loss of Als3 adhesive function.
Conclusion: The PBC is required for Als3 adhesive function.
Significance: Interfering with PBC function is a viable strategy for inhibiting C. albicans adhesion.
The adhesive phenotype of Candida albicans contributes to
its ability to colonize the host and cause disease. Als proteins are
one of the most widely studied C. albicans virulence attributes;
deletion of ALS3 produces the greatest reduction in adhesive
function. Although adhesive activity is thought to reside within
the N-terminal domain of Als proteins (NT-Als), the molecular
mechanism of adhesion remains unclear. We designed muta-
tions in NT-Als3 that test the contribution of the peptide-bind-
ing cavity (PBC) to C. albicans adhesion and assessed the adhe-
sive properties of other NT-Als3 features in the absence of a
functional PBC. Structural analysis of purified loss-of-PBC-
function mutant proteins showed that the mutations did not
alter the overall structure or surface properties of NT-Als3.
The mutations were incorporated into full-length ALS3 and
integrated into the ALS3 locus of a deletion mutant, under
control of the native ALS3 promoter. The PBC mutant phe-
notype was evaluated in assays using monolayers of human
pharyngeal epithelial and umbilical vein endothelial cells,
and freshly collected human buccal epithelial cells in suspen-
sion. Loss of PBC function resulted in an adhesion phenotype
that was indistinguishable from the als3/als3 strain. The
adhesive contribution of the Als3 amyloid-forming-region
(AFR) was also tested using thesemethods.C. albicans strains
producing cell surface Als3 in which the amyloidogenic
potential was destroyed showed little contribution of the AFR
to adhesion, instead suggesting an aggregative function for
the AFR. Collectively, these results demonstrate the essential
and principal role of the PBC in Als3 adhesion.
Candida albicans is the most common cause of opportunis-
tic mycoses worldwide (1). Among these conditions are
oropharyngeal candidiasis that afflicts many HIV-infected
patients, vaginal thrush, and denture stomatitis (2–4).Candida
spp. are among the top four pathogens causing nosocomial
bloodstream infections (5), which carry mortality rates ranging
between 30 and 40% (1, 6). Cell surface glycoproteins in the C.
albicans Als family (Als1–Als7 and Als9) are most commonly
associated with adhesion of the fungus to host cells, as well as
more complex interactions such as invasion and biofilm forma-
tion, for which adhesion is a prerequisite (7–9). Deletion ofALS
genes fromC. albicans or expression ofALS genes in Saccharo-
myces cerevisiae leads to reduction or gain of adhesive function,
respectively (10, 11).
The N-terminal domain of Als proteins (NT-Als)4 was impli-
cated in adhesive function (12, 13), prompting work to solve its
structure (14). X-ray crystallographic analysis of NT-Als9-2
(encoded by anALS9 allele) showed that it is characterized by two
immunoglobulin-like domains and possesses a peptide-binding
cavity (PBC) that can bury up to 6 residues from flexible C termini
of polypeptides (14). An invariant Lys (Lys-59) at the end of the
PBC recognizes the carboxyl group at the C terminus of a peptide
ligand, allowing the remaining peptide backbone to associate in
parallel orientation with -strandG2. In the structure of different
NT-Alsligand complexes, several water molecules anchor poly-
peptides with different C-terminal sequences in the PBC. These
structural observations suggest that the PBC is responsible for Als
adhesive interactions and may account for the ability of Als pro-
teins, particularly Als3, to bind to the numerous ligands docu-
mented in the literature (e.g. 2–4, 12–16).
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Here, we describe use of the NT-Als9-2 structure to guide a
mutagenesis strategy aimed at disrupting PBC function in Als3.
Als3was selected for this analysis because deletingALS3 results
in a larger decrease in C. albicans adhesion than for any other
gene in the family (10). We also targeted the NT-Als C termi-
nus, which contains a conserved amyloid-forming region (AFR)
(15) for which adhesive properties have been proposed in the
literature (16).Weused biophysical techniques to solve theNT-
Als3 structure and assessed the structural impact of the site-
directed mutations. Finally, we produced the mutant Als3 pro-
teins on the C. albicans surface, under control of the native
ALS3 promoter, and tested the strains for their adhesive phe-
notype in assays using cultured or freshly collected human cells.
The complementary information provided from the study of
purified proteins using biophysical techniques and phenotypic
analysis of mutant proteins displayed in native conditions on
theC. albicans surface demonstrates the essential contribution
of the PBC to Als3 adhesive function.
EXPERIMENTAL PROCEDURES
DNAConstructs, Protein Expression, and Purification—DNA
encoding the N-terminal domain of Als3 (NT-Als3, amino
acids 1–315 of the mature protein, KTIT—IVIVA, GenBank
Accession No. AY223552), was subcloned in plasmid pET32-
Xa-LIC by ligation-independent cloning (Novagen). From this
construct, a shorter version ofNT-Als3 that excludes theC-ter-
minal AFR (sNT-Als3), was generated by replacing the codon
corresponding to Asn-303 with a stop codon. Other mutations
that probe the function of the PBC and the AFR in these con-
structs are summarized in Fig. 1. Mutagenesis was performed
with the QuikChange II Kit (Agilent Technologies). Oligonu-
cleotides were designed according to the manufacturer’s
instructions. Expression and purification of unlabeled and
U-15N-labeledNT-Als3 constructs/mutantswere performed as
described for NT-Als1 (17). DNAs were transformed for pro-
tein expression in the Origami Escherichia coli strain (New
England Biolabs) and grown at 37 °C in LB agar plates with 50
g/ml carbenicillin, 15 g/ml kanamycin, and 12.5 g/ml tet-
racycline. Cultures grown in thismediumwere clarified by cen-
trifugation at 2000  g and the cell pellets resuspended in 500
ml of LB or M9 minimal medium with 0.07% w/v 15N ammo-
nium chloride (Spectra Gases) plus carbenicillin and kanamy-
cin for expression of uniformly labeled 15N proteins. Cell cul-
tures at an A600 0.5–0.7 were induced with 0.5 mM isopropyl
1-thio--D-galactopyranoside and left to grow at 18 °C over-
night. Cells were then harvested by centrifugation, resuspended
in ice-cold 50 mM Tris, pH 8, 300 mM NaCl plus Complete
protease inhibitor (Roche Applied Science), and lysed by
French press. The lysate was centrifuged at 30,000  g for 20
min to obtain a cleared supernatant. Soluble thioredoxin-His6-
Als3 fusions were affinity-purified using nickel-nitrilotriacetic
acid resin (Qiagen) in 50mMTris, pH 8.0, 300mMNaCl, 10mM
imidazole, and eluted with 50mMTris, pH 8, 300mMNaCl, 250
mM imidazole. The N-terminal thioredoxin and His6 tags were
removed fromAls3 proteins by Factor Xa (Novagen) and a sec-
ond nickel affinity purification. Als3 proteinswere further puri-
fied by size exclusion chromatography on a HiLoad 16/60
Superdex 75 column (GE Healthcare) in 50 mM Tris, pH 8.0,
and 300 mM NaCl.
NMR Experiments—Samples for NMR experiments were
dialyzed extensively against 50 mM sodium phosphate buffer,
pH 8.0, 50 mM NaCl and concentrated to 200 M protein. 10%
D2O was added to lock the deuterium signal. Proton and 15N
TROSY-HSQC spectra were recorded at 308 K on a Bruker 800
MHz Avance II spectrometer equipped with a TXI Cryoprobe
(Cross Faculty NMR Centre, Imperial College London).
Isothermal Titration Calorimetry—ITC experiments were
carried out in a VP-ITCMicroCalorimeter (Microcal). Binding
isotherms were obtained upon titration of 2.8 mM hepta-Thr
(Biomatik) into solutions of 100 M sNT-Als3 or sNT-Als3-gk.
Titrationswere conducted in 50mM sodiumphosphate, pH 6.0,
and 150 mM NaCl at 303 K. Prior to ITC analysis, protein sam-
ples in 3 M urea were dialyzed twice against the buffer above to
remove proteins/peptides bound to sNT-Als3 and sNT-
Als3-gk during protein purification.
Crystallization—sNT-Als3 (10 mg/ml) in 20 mM Tris-HCl,
pH 8.0, 100mMNaCl was incubatedwith 100-foldmolar excess
hepta-Thr (sNT-Als3/hepta-Thr) crystallized at 293 K by sit-
ting drop vapor diffusion against 20% v/v PEG 400, 30% w/v
PEG 4000, 100 mM sodium citrate, 50 mM ammonium acetate,
pH 5.6. NT-Als3-pbc (10 mg/ml) in 20mMTris-HCl, pH 8, 100
mM NaCl was crystallized at 293 K by sitting drop vapor diffu-
sion against 25% w/v PEG 4000 and 30% v/v ethylene glycol.
sNT-Als3/hepta-Thr crystals were brieflywashed in paraffin oil
before flash freezing in liquidN2. Crystals of NT-Als3-pbcwere
flash frozen straight in liquid N2.
X-ray Data Collection, Structure Solution, and Refinement—
Data for sNT-Als3/hepta-Thr were collected at 100 K on sta-
tion I04-1 of the Diamond Light Source, UK. Data were pro-
cessed usingXDS (18) and then scaledwith SCALA (19), within
XIA2 (20). Initial phases were calculated with molecular
replacement with NT-Als9-2 (Protein Data Bank ID code
2Y7N) (14) as the search model using MOLREP (21). Model
FIGURE 1. Als3 constructs and mutants for structural analysis. Top, as a
reference, the arrangement of domains in full-length Als3 is shown to scale:
the signal sequence (pink) is followed by the N-terminal region, containing
the amyloid-forming region (red and blue, respectively), the threonine-rich
region (light gray), the central repeats (light green), and the C-terminal region
(dark gray). Bottom, an expanded N-terminal region is used to show the loca-
tion of Als3 mutants and the truncation at the C terminus (CT) to remove the
AFR in sNT-Als3 and sNT-Als3-gk. The numbering of amino acids is consistent
with the alignment of mature Als proteins described previously (14).
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building was carried out in COOT (22), and refinement with
TLS groups (23) was done in REFMAC (24), where 5% of the
reflections were omitted for cross-validation. The final model
contains 1 molecule of hepta-Thr in the asymmetric unit, and
all residues could be built except for the C-terminal Arg-302
(sNT-Als3) and the side chains of Lys-1, Lys-75, Lys-106, Lys-
132, Lys-148 (sNT-Als3), and Thr-1 (hepta-Thr).
Data for NT-Als3-pbc were collected at 100 K on station I24
of the Diamond Light Source, UK. Data were processed using
XDS (18) and then scaled with SCALA (19), within XIA2 (20).
The presence of twinning and significant pseudotranslational
symmetry (u  0.01, v  0.23, w  0.5) was detected using
XTRIAGE (25). Initial phases were calculated with molecular
replacement with NT-Als9-2 as the search model using
MOLREP (21). Model building was carried out in COOT (22)
and refinement with TLS groups (23), NCS, and twin refine-
ment (a  0.49) was done in REFMAC (24), where 5% of the
reflections were omitted for cross-validation. The final model
contains 4 molecules of NT-Als3-pbc in the asymmetric unit,
and all residues could be built except for the C-terminal Thr-
313 (all chains) and the side chains of Lys-1, Asn-53, Lys-75,
Lys-106, Glu-129, Lys-132, Lys-148, Lys-149, Tyr-203, Lys-219,
Glu-231, Glu-278, Arg-288, Phe-298 (chain A); Lys-1, Lys-106,
Glu-129, Lys-132, Asp-145, Lys-148, Lys-149, Lys-164, Lys-
178, Gln-207, Lys-219, Glu-231, Tyr-285 (chain B); Lys-1, Lys-
75, Lys-106, Lys-132, Lys-148, Lys-164, Lys-178, Gln-187,Met-
197, Lys-237, Lys-249, Asn-250, Tyr-285 (chain C); and Lys-1,
Lys-75, Lys-106, Lys-132, Lys-148, Arg-158, Lys-164, Arg-294
(chainD). Processing and refinement statistics of the finalmod-
els are in Table 1.
Strain Construction—C. albicans strains that produce
mutant Als3 proteins weremade using constructs in amodified
version of the plasmid pUL (11). All PCR amplifications used
SC5314 genomic DNA as template and proofreading polymer-
ase. Primers ALS3dnF and ALS3dnR (Table 2) were used to
amplify a 358-bp fragment downstream of the ALS3 coding
region. The resulting PCR product was digested with SstII-
NgoMIV and cloned into identically digested pUL, resulting in
plasmid 1765. Primers were synthesized to add a polylinker to
plasmid 1765, expanding its 5 end multiple cloning site to
include HindIII-PstI-BamHI-NcoI-XhoI-SphI. The resulting
plasmid was named 2303. Primers 3upPstF and 3upBamRwere
used to amplify a fragment that includes sequences from
upstream of the ALS3 coding region as well as the first 141
nucleotides of ALS3. This fragment was digested with PstI-
BamHI and cloned into identically digested plasmid 2303, pro-
ducing plasmid 2329. Another portion of the ALS3 5 domain
was amplified using primers 3cdBamF and 3cdNcoR. The prod-
uct was digested with BamHI-NcoI and cloned into plasmid
2329, yielding plasmid 2370. The remainder of theALS3 coding
region was amplified using primers 3cdNcoF and 3dnXhoR,
digested with NcoI-XhoI, and cloned into plasmid 2370. The
resulting plasmid (2386) included the entire ALS3 coding
region, with flanking sequences to direct integration into the
ALS3 locus, and theURA3 selectable marker. TheALS3 coding
region included BamHI and NcoI sites within the 5 domain to
provide easy swapping of cassettes encoding mutant ALS3
sequences. Gene fragments encoding the desired mutations
were synthesized by Genewiz Inc., digested with BamHI-NcoI,
and cloned into plasmid 2386 to replace the wild-type
sequence. The DNA sequence of each resulting construct was
verified, and the plasmidwas digested with PstI-SstI to produce
a fragment for transformation of the C. albicans als3/als3
ura3/ura3 strain 2311 (13). Methods for transformation and
TABLE 1
Crystallographic data and refinement statistics
Numbers in parentheses refer to the outermost resolution shell.
sNT-Als3/hepta-Thr NT-Als3-pbc
Crystal parameters
Space group P21 P21
Cell dimensions a 49.4, b 58.2,
c 57.2,  114.5
a 112.6, b 67.1,
c 112.7,  103.5
Data collection
Beamline DLS I04–1 DLS I24
Wavelength (˚) 0.9173 0.9790
Resolution (˚) 1.40–29.09 (1.40–1.48) 3.00–48.33 (3.00–3.08)
Unique observations 53890 (7562) 32262 (2312)
Rsyma 0.054 (0.179) 0.097 (0.398)
I/I 17.8 (7.7) 9.6 (2.7)
Completeness (%) 93.1 (89.9) 97.5 (95.5)
Redundancy 6.6 (6.8) 2.8 (2.8)
Refinement
Rwork/Rfree b (%) 13.6/17.7 22.9/24.2
Number of protein
residues
605 1252
r.m.s.d. stereochemistryc
Bond lengths (˚) 0.019 0.009
Bond angles (°) 1.762 1.439
Ramachandran analysisd
Residues in outlier
regions
0 0
Residues in favored
regions
97.0% 93.7%
Residues in allowed
regions
100% 100%
aRsym 	II/	I where I is the integrated intensity of a given reflection and
I is the mean intensity of multiple corresponding symmetry-related
reflections.
b Rwork 	Fo Fc/	Fo where Fo and Fc are the observed and calculated struc-
ture factors, respectively. Rfree Rwork calculated using
5% random data ex-
cluded from the refinement.
c r.m.s.d. stereochemistry is the deviation from ideal values.
d Ramachandran analysis was carried out using MOLPROBITY (40).
TABLE 2
Oligonucleotide primers used for C. albicans strain construction
Primer Sequence (5–3)
ALS3dnF CCC CCG CGG AAG AGC CTG CGA CTA TGA
ATT G
ALS3dnR CCC GCC GGC GTT TGG TAA TTA ACA CAT
ATT GC
3upPstF CCC CTG CAG GTT TTG CTA TGC ACG TTC
ATA CTT CC
3upBamR AAG TTG GGG ATC CTG GTC CCT TAT AAT
3cdBamF AAT ATA AGG GAC CAG GAT CCC CAA CTT
GGA ATG CTG TT
3cdNcoR GTT TTG TCG CGGTTA GGA TCC CAT GGT AA
3cdNcoF TTA CCA TGG GAT CCT AAC CGC GAC AAA AC
3dnXhoR CCC CTC GAG CCT TAA ATA AAC AAG GAT
AAT AAT GTG
3upPstF CCC CTG CAG GTT TTG CTA TGC ACG TTC
ATA CTT CC
3upFixBamR AAC AGC ATT CCA AGT TGG GGT TCC TGG
TCC CTT ATA AT
3upFixBamF ATT ATA AGG GAC CAG GAA CCC CAA CTT
GGA ATG CTG TT
3cdFixNcoR GTT TTG TCG CGG TTA GGA TCG AAT GGT
AAG GTG GTC AC
3cdFixNcoF GTG ACC ACC TTA CCA TTC GAT CCT AAC
CGC GAC AAA AC
3dnXhoRPlus CCC CTC GAG CCT TAA ATA AAT AAG GAT
AAT AAT GTG ATC AAA CCA C
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verification of constructs by Southern blotting and PCR were
described previously (11). The resulting C. albicans strains
were also validated by immunolabeling with anti-Als3 mono-
clonal antibody 3-A5 using published methods (26).
Because the BamHI and NcoI restriction sites introduced
amino acid changes into the NT-Als3 sequence, the entire
strain set was reconstructed following PCR mutagenesis to
restore the restriction sites to the wild-type sequence. Q5 DNA
polymerase was used in all reactions. PCR products were
treated with GeneClean (MP Biomedicals) prior to their use as
templates in subsequent PCRs.
UsingDNA from construction of the original strain set as the
template, three different PCRswere performed for eachmutant
gene. Primers 3upPstF and 3upFixBamR (Table 2) amplified a
340-bp fragment including theALS3 upstream and 5 sequence
(product A). Primers 3upFixBamF and 3cdFixNcoR amplified a
900-bp fragment from theALS3 5domain (product B). Primers
3cdFixNcoF and 3dnXhoRPlus amplified the remainder of the
ALS3 coding region as well as some downstream sequence (2.4
kb total; product C). Primers 3upPstF and 3cdFixNcoR were
used to amplify a 1.24-kb fragment (product D) from a mixed
template of productsA andB.Amix of productsC andD served
as template for amplification with primers 3upPstF and
3dnXhoRPlus to generate a fragment (product E; 3.64 kb)
encoding ALS3 with the correct mutant sequence as well as
upstream and downstream regions for integration into the
ALS3 locus of strain 2311. Prior to transformation, product E
was cloned into pJET1.2 (CloneJET PCR Cloning Kit; Thermo
Scientific), and its DNA sequence was verified. Each plasmid
was digested with PstI-XhoI and cloned into similarly digested
plasmid 2386 (described above). These constructs were
digested with PstI-SacI and the resulting fragment transformed
into C. albicans 2311. Transformant screening and verification
by immunolabeling with anti-Als3 3-A5 were as described
above. Primers 3upPstF and 3dnXhoRPluswere used to amplify
genomic DNA from each candidate strain, and the DNA
sequence of each integrate construct was verified. The resulting
strains (Table 3) were used in this study.
Adhesion Assays—Methods for evaluating C. albicans adhe-
sion to cultured human umbilical vein endothelial cells and
freshly collected human buccal epithelial cells were published
previously (11). Adhesion to cultured FaDu cells was assayed as
described previously (27). Assays were conducted at least in
replicate on at least 3 different days.
RESULTS
Effects of the PBC and AFR on Aggregation of Purified
NT-Als3—Nuclear magnetic resonance (NMR) was used to
analyze the structure of NT-Als3 (amino acids 1–315 of the
mature protein; amino acids are numbered using a previously
described method (14)). A 1H-15N TROSY-HSQC spectrum
of NT-Als3 revealed reduced solubility and broadening of
NMR lines beyond signal detection (Fig. 2A). Removal of the
C-terminal AFR to form sNT-Als3 (amino acids 1–302)
resulted in a folded protein that was monomeric in solution,
with excellent dispersion of amide resonances (Fig. 2B).
These observations were potentially attributable to oligo-
merization caused by NT-Als3 binding of the free C-termi-
nal peptide of adjacent molecules or to aggregationmediated
by amyloid-forming regions of the molecules. To distinguish
between these possibilities, we designed mutations to inter-
fere with PBC and/or AFR function. Because NT-Als9-2 and
NT-Als3 are 68% identical, we used the NT-Als9-2 structure
as a reference to design NT-Als3 mutations that create a
hydrophobic patch at the end of the PBC, replacing the
hydrophilic contacts established with the C-terminal car-
boxyl group of polypeptides. Specifically, Tyr-301 and Thr-
116 side chains that flank Lys-59, positioning its side chain
for interaction with ligands (14), were mutated to hydropho-
bic residues. NMR analysis showed that mutations in
NT-Als3-pbc (K59M, A116V, Y301F) shift the conforma-
tional equilibrium toward a monomeric, nonaggregated
form of the protein that facilitates structural analysis (Fig.
2C). Inclusion of two additional mutations (I311S/I313S)
was predicted to suppress the amyloidogenic propensity of
the AFR, as judged by TANGO analysis (28), and successfully
removed the residual NT-Als3 aggregative activity (Fig. 2D).
A Triple Mutation in the PBC Stabilizes the Ligand-bound
Conformation of NT-Als3—Previous structural analyses showed
that the PBC of purifiedNT-Als adhesins invariably is occupied
by a ligand, either exogenously added as in the structure of
NT-Als9-2 in complex with a human fibrinogen- peptide
TABLE 3
C. albicans strains used in this work
C. albicans strains ALS3 genotypea Reference Comments
CAI12 ALS3LA/ALS3SA (31) Encodes two wild-type ALS3 alleles.
1893 ALS3LA (27) Encodes only ALS3LA.
1843 als3/als3 (11) Complete deletion of both ALS3 alleles.
3464 als3/als3::ALS3LA This work Encodes only ALS3LA.
3465 (Als3-pbc) als3/als3::ALS3LA (K59M/A116V/Y301F) This work Mutations in the PBC create the structure of NT-Als3
bound to a ligand, even in the absence of a peptide.
The AFR is not free in solution, but associated with
the folded portion of the NT-Als3 domains.
3466 (Als3-gk) als3/als3::ALS3LA (S170Y) This work A gatekeeper mutation blocks the entrance of the PBC,
eliminating ligand binding. The AFR is not
affected and remains free in solution.
3467 (Als3-afr) als3/als3::ALS3LA (I311S/I313S) This work Mutations abolish the amyloidogenic potential
of the AFR, but do not affect the PBC.
3468 (Als3-pbc-afr) als3/als3::ALS3LA (K59M/A116V/Y301F/I311S/I313S) This work Combined mutations as in strains 3465 and 3467.
PBC and AFR function are abolished.
a ALS3 alleles are designated as ALS3LA or ALS3SA depending on whether they include 12 or 9 copies of the 36-amino acid tandem repeat sequence in the central domain of
the protein (11). ALS3LA alleles (1138 amino acids) are preferred for these experiments because the increased tandem repeat copy number is believed to form a longer,
more extended protein that projects the NT-Als3 domain further away from the cell surface, making it more accessible for functional interactions (11).
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(NH3-GEGQQHHLGGAKQAGDV-CO2), or via self-comple-
mentation with its ownC-terminal strand (Fig. 3,A and B) (14).
The crystallographic structure of NT-Als3-pbc revealed that
the mutated residues in the PBC maintained the orientation
of the wild-type side chains, but created a hollow, ligand-free
cavity (Fig. 3C). Unexpectedly, the new interactions in this
mutant protein also acted as a “zipper” that propagated the
contacts of the flexible C terminus over the surface of the adhe-
sin. Therefore, NT-Als3-pbc recreated the conformation
observed in the NT-Als9-2Fg- complex, even in the absence
of exogenous ligand. Importantly, themutated side chains were
buried in the PBC, and as a result, NT-Als3-pbc retained sur-
face properties of the wild-type protein (Fig. 3D).
sNT-Als3, Which Lacks the AFR, Is Competent for Ligand
Binding—The crystal structure of sNT-Als3 (amino acids
1–302) in complex with the model peptide hepta-Thr showed
that removal of theC-terminalAFRdid not affect the formation
of a fully functional PBC (Fig. 3E). Notably, the side chain amine
of Lys-59 formed a salt bridge with the C-terminal carboxylate of
the hepta-Thr ligand, and at least 12 hydrogen bonds between
the peptide in extended conformation and this binding cavity
were connected via water molecules, resembling the mode of
interaction observed in the structure of the NT-Als9-2Fg-
complex (Fig. 3A). In the residues comprising the immunoglob-
ulin “core” (amino acids 1–299 of the mature protein (14)), this
construct had the same overall structure as NT-Als3-pbc, with
a r.m.s.d. of 0.9 Å for 296 C carbons (DaliLite (29)). When
hepta-Thr was bound in the PBC, the Tyr-301 side chain was
exposed to the solvent and did not contact Lys-59, possibly
from electrostatic repulsion experienced by unpaired charges
of the carboxyl group and side chain of Arg-302 at the C termi-
nus. The observation that sNT-Als3 bound hepta-Thr was con-
firmed in solution by ITC (Fig. 4A).
AGatekeeperMutant (S170Y) Stabilizes the Ligand-free Con-
formation of NT-Als3—Purified N-terminal fragments of Als5
or small synthetic peptides containing the Als5 AFR induce
aggregation of yeast cells that display Als5 on the surface (30).
To better define AFR functional contributions, we sought to
createNT-Als3mutant proteins thatwould separateAFR activ-
ity from those of the PBC. At the entrance of the Als3 PBC is
Ser-170, a position almost invariably occupied by Ser or Ala
among C. albicans Als proteins. Mutant S170Y (NT-Als3-gk)
was designed as a “gatekeeper” to hinder access of peptides at
the entrance of the PBC. Without bound peptide, the C-termi-
nal AFR should be fully flexible and exposed for amyloidogenic
interactions. ITC experiments demonstrated that unlike wild-
type sNT-Als3, the nonaggregative form of this mutant protein
(sNT-Als3-gk, amino acids 1–302) was incapable of binding
hepta-Thr (Fig. 4B).
Proton NMR spectra showed that the immunoglobulin core
of thismutantwas folded in solution and comparablewithwild-
type sNT-Als3 (Fig. 4,C andD). Unexpectedly, extension of this
FIGURE 2.NMR spectra (1H-15N TROSY-HSQC) showing the effect of mutations in the PBC and AFR on NT-Als3. A, the NMR spectrum of purified NT-Als3
showed considerably reduced solubility. Two potential mechanisms explain this effect: oligomerization caused by insertion of the free C terminus (CT) of the
protein as a ligand into the binding pocket of an adjacent NT-Als3 molecule (“self-complementation,” left) (14) and aggregation mediated by exposed AFR
sequences (30). Note that self-complementation is suppressed in full-length Als proteins on the C. albicans surface, where the C terminus is linked to the cell
wall via a glycosylphosphatidylinositol anchor remnant (10). B, deletion of the AFR resulted in sNT-Als3, a construct free of oligomerization and aggregation
effects. C, mutations in the PBC (K59M, A116V, and Y301F to generate NT-Als3-pbc) improved protein solubility compared with A, presumably due to
elimination of self-complementation and decreased aggregation because the AFR was associated with the rest of the NT-Als3 folded structure (Fig. 3). D,
solubility of the protein in Cwas further improved by removing residual AFR activity viamutations I311S/I313S (NT-Als3-pbc-afr). These results demonstrate at
the molecular level the role of the PBC and the AFR in aggregation among purified NT-Als proteins.
Mechanism of C. albicans Als3 Adhesion to Human Cells
JUNE 27, 2014•VOLUME 289•NUMBER 26 JOURNAL OF BIOLOGICAL CHEMISTRY 18405
 at Im
perial College London on February 18, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
mutant with the C terminus containing the AFR (NT-Als3-gk,
amino acids 1–315) did not lead to aggregation observed in
wild-type NT-Als3 (Fig. 4, E and F, respectively), which indi-
cated that disrupting the function of the PBC greatly decreased
in vitro self-complementation as a mechanism for aggregation
ofNT-Als3. Collectively, these results suggested that the S170Y
mutant provided a stable, ligand-free form of NT-Als3.
The PBC Drives Als3-mediated C. albicans Adhesion—The
site-directed mutations described above were placed into full-
length ALS3 genes and integrated individually into the ALS3
locus in a als3/als3 background. Visualization of Als3 local-
ization and relative abundance on the C. albicans cell surface
were accomplished by immunolabeling of the resulting strains
with the NT-Als3-specific monoclonal antibody 3-A5 (26). For
each strain, distribution of Als3 on the C. albicans germ tube
surface resembled the control strains (Fig. 5A). Relative abun-
dance of Als3 varied depending on whether the strain encoded
two ALS3 alleles (CAI12 (31)), one ALS3 allele (1893 (27)), or
had one allele reintegrated into a null mutant using the cassette
for producing the mutant proteins (3464). Strain CAI12 had
more Als3 protein than strain 1893; strains 3464 through 3468
exhibited a slight reduction in Als3 protein compared with
strain 1893, but showed levels similar to each other (Fig. 5A).
Each C. albicans strain was tested in assays for adhesion to
cultured monolayers of human umbilical vein endothelial cells
(Fig. 5B) and FaDu cells, Fig. 5C), as well as freshly collected
buccal epithelial cells (BECs; Fig. 5D). Because strain 3464 was
the most closely related to the strains producing mutant Als3
proteins, it was the best control for interpretation of the adhe-
sion assay data. In all adhesion assays, strains with a mutated
PBCwere statistically indistinguishable from the null (deletion)
mutant 1843. These results indicated that the PBCwas essential
FIGURE 3. Crystal structures of NT-Als3-pbc and sNT-Als3. A and B, the structures of NT-Als9-2 in complex with Fg- peptide and in free form (14) are
displayed as a reference to illustrate the effect ofmutations in the PBC of NT-Als3. C, the crystal structure of NT-Als3-pbc shows awell formed, empty PBC. Inset
below, the mutated side chains form a hydrophobic patch in the PBC. D, surface representation of NT-Als3-pbc is rotated 45° clockwise in the x axis relative to
C. The inset below shows the mutated side chains at the end of the PBC. E, diagram shows sNT-Als3 in complex with a hepta-Thr ligand. F, detail shows
interactions between the sNT-Als3 binding site and hepta-Thr. Secondary structure elements that form the binding site are labeled as previously (14) and
colored as in C. Red spheres represent watermolecules. Sigma-Aweighted Fo Fc omitmap for these structural models (generated using simulated annealing
within PHENIX) were contoured at 3 Å r.m.s.d. electron density around the C terminus andmutated residues in NT-Als3-pbc (A and B), and at 1.6 Å r.m.s.d. for
the hepta-Thr peptide in sNT-Als3. Details of x-ray crystallographic data collection, processing, and structure refinement are in Table 1.
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for Als3-mediated adhesive function, without adhesive contri-
bution from the AFR.
Adhesion assay data suggested an effect of protein abun-
dance on the assay results. Strain CAI12 (with two ALS3 alleles
and the greatest abundance of Als3) consistently showed the
greatest amount of adhesion. Loss of an ALS3 allele led to less
Als3 and a reduction in adhesion, with a notable difference
occurring between strains 1893 and 3464. Both of these strains
encoded the same ALS3 allele, suggesting that the difference in
protein abundance was attributable to integration of the clon-
ing cassette into the ALS3 locus of strains 3464 through 3468.
The effectwas assay-dependentwith the least effect observed in
the BEC assay and a more pronounced change noted in the
monolayer assays.
The Role of the Als3 AFR Is More Aggregative Than Adhesive—
Mutations that abolish the amyloidogenic potential of the AFR
were created to test the contribution of the AFR to Als3 func-
tion in the adhesion assays. The NT-Als3-pbc structure
revealed that the side chains of Ile-311 and Ile-313 in the AFR
were exposed to the solvent and did not stabilize the interaction
of the C-terminal -strand with the NT-Als surface (Fig. 6).
Double mutant I311S/I313S (NT-Als3-afr) was predicted to
suppress the amyloidogenic potential of the AFR, as judged by
TANGO analysis (28) and, when incorporated into the
NT-Als3-pbc sequence (K59M, A116V, Y301F, I311S, I313S;
NT-Als3-pbc-afr), removed the residual aggregative tendency
of the protein (Fig. 2, C and D).
Als3-afr and Als3-pbc-afr were integrated intoC. albicans to
test their adhesion phenotype. Strain 3468 (Als3-pbc-afr) was
statistically indistinguishable from strain 3465 (Als3-pbc) in all
assays (Fig. 5), suggesting that in the absence of PBC function,
AFR activity is not sufficient to affect adhesion assay results.
Phenotypic observations for strain 3467 (Als3-afr) were more
complex. In the human umbilical vein endothelial cells and
FIGURE 4. Biophysical characterization of the S170Y (NT-Als3-gk and sNT-Als3-gk) proteins. A, the interaction of sNT-Als3 and hepta-Thr using ITC is
indicated by a reduction of the heat signal as the protein was saturated with ligand. In these conditions, isotherms yielded a low sigmoidicity (or c value),
precluding the accurate determination of thermodynamic parameters. B, sNT-Als3-gk showed no appreciable heats of injection relative to a blank titration,
indicating the loss of peptide-binding activity uponmutation. C andD, the proton spectrumof sNT-Als3-gk (C) displays comparable linewidths and dispersion
of signals to sNT-Als3 (D) in the methyl/methylene region, showing that mutation S170Y does not affect the structure of the protein. E and F, the NT-Als3-gk
fragment, extended with the C-terminal residues containing the AFR (E), does not induce the aggregation observed in wild-type adhesin, NT-Als3 (F).
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FIGURE 5. Adhesion phenotype of C. albicans strains displaying mutant Als3 proteins. A, immunofluorescent labeling of C. albicans germ tubes with
anti-NT-Als3 to visualize display ofwild-type ormutant Als3 proteins on the cell surface. Labeling intensitywas different between control strainswith twoALS3
alleles (CAI12), one ALS3 allele (1893), and no ALS3 alleles (1843). Strains producing mutant proteins Als3-pbc (3465), Als3-gk (3466), Als3-afr (3467), or
Als3-pbc-afr (3468) showed labeling intensity similar to their wild-type control strain 3464; however, labeling of each of these strains was less than for strain
1893, which also encoded one ALS3 allele. B–D, incubation of strains lacking PBC function showing significantly decreased adhesion tomonolayers of human
umbilical vein endothelial cells (B), humanpharyngeal epithelial cells (FaDu;C) or in suspensionwith freshly collected humanbuccal epithelial cells (D). Results
for Als3 lacking only AFR functionweremore complex, likely reflecting the influence of C. albicans cellular aggregation on each adhesion assay (see “Results”).
In each histogram, different lowercase letters are used to denote strains for which adhesion results are statistically significantly different (p 0.05). In B, the
asterisk indicates that strain 3467 is significantly different from strain CAI12, but not from strain 1893. Results are reported as means S.E. (error bars).
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FaDu monolayer assays, 3467 showed increased adhesion rela-
tive to the control strain (3464), suggesting that the AFR inhib-
ited Als3 adhesion. This effect may occur if the AFR caused
aggregation between Als3molecules on theC. albicans surface.
As a result, we hypothesize that a decrease in the aggregative
potential of the AFR by the I311S/I313S mutant made the PBC
more accessible for interactions with host cell ligands. Germ
tubes for these assays were grown statically and transferred to
cell culture wells containing the host cell monolayer to test the
adhesive phenotype. Microscopic inspection of the cell culture
wells indicated that germ tubes adhered individually in this
static assay. In contrast, results for the BEC assay showed
decreased adhesion of strain 3467 (Als3-afr) relative to the con-
trol strain (3464), suggesting that the AFR promoted adhesion.
Germ tubes for this assay were grown in a shaking flask, to
which the BECs subsequently were added and co-incubated.
Adhesionwas evaluated bymicroscopy, counting germ tubes in
direct contact with a BEC as adherent. In contrast to themono-
layer assays (above), germ tubes in the BEC assay formed aggre-
gates that adhered to the human cells. Each aggregate brought
many germ tubes into close proximity with the BEC, providing
the potential for a higher count of “adherent” cells. Germ tubes
of strain 3464 that adhered to BECs were significantly more
aggregated than those of strain 3467 (7.7 0.7 cells/aggregate
compared with 5.2  0.7, p  0.05). In addition, although not
statistically significant, more germ tubes of strain 3467 adhered
to BECs individually (mean  40.3  2.8 of 100 adhesion
events) than germ tubes of strain 3464 (29.3  2.8; p  0.1).
Collectively, these observations were consistent with the con-
clusion that the Als3 AFR mediated interactions between Als
molecules on the same C. albicans cell, as well as between C.
albicans cells, contributing aggregative, rather than adhesive,
effects. These data also illustrated the contribution of aggrega-
tive interactions to commonly used assays for evaluating C.
albicans adhesion.
Sequence-based Structural Predictions and Als Ligand-bind-
ing Specificity—Data presented here demonstrated the princi-
pal role of the PBC in Als adhesion, an initial step toward a
mechanistic understanding of Als function. The PBC-mediated
adhesive mechanism can explain the ability of Als proteins to
bind a wide variety of peptide ligands. Work presented here
provided a second high resolution NT-Als structure and
prompted an examination of amino acids with side chains pre-
dicted to interact with ligands in the PBC of the other Als pro-
teins (Fig. 7). Barring significant changes in the NT-Als protein
backbone conformation, variable amino acids with side chains
in close proximity with ligands should modulate changes in
binding specificity across the Als family. Of note, NT-Als1 and
NT-Als3 (themost conserved pair of NT-Als proteins with 83%
identity in this region) differed in positions 22, 28, and 168,
suggesting that their individual ligand-binding specificities can
be transferred from one adhesin to another with a minimal
number of amino acid substitutions. In contrast, NT-Als7 had
45% amino acid identity with NT-Als3 and 11 changes in this
amino acid subset. Future experiments will focus on exploring
these relationships, which are expected to further verify the
importance of the PBC to Als adhesive function, and define
functional interrelationships among the family of Als proteins.
FIGURE 6. Position of amino acids substituted to abolish AFR function.
The side chains of residues Ile-311 and Ile-313were exposed to solvent in the
structure of NT-Als3-pbc (left), which recreated the conformation of the
ligand-bound form of the protein, as shown in the structure of NT-Als9-2 in
complex with Fg- peptide (14) right). For comparison, the equivalent resi-
dues in NT-Als9-2 (Asp-311 and Ile-313) are shown. Substitution of Ser for
each Ile residue in NT-Als3 eliminated the amyloidogenic propensity of the
AFR, as predicted by TANGO (28).
FIGURE 7. Alignment of NT-Als PBC residues with side chains that interact with peptide ligands. The structures of NT-Als9-2 and NT-Als3 allowed
prediction across theAls family of amino acidswith side chains in closeproximity to ligands in the PBC. These residues arehighlighted in theAls3 sequence (left)
and include residues 19, 22, 27, and 28 in the A1-B1 loop that act as a “lid” over the binding cavity; residues 61 and 116 (-strands C1* and E1, respectively) that
flank the invariant Lys-59 (highlighted in blue); residues 166, 168, 170, and 172 in the A2-strand; residues 294, 295, 296, and 298 in the G2b-strand.Numbers
on top of the alignment show the substitutions observed in the family, with positions 22 and 168 containing the greatest sequence diversity. Residues
highlighted in the alignment are mapped in the sNT-Als3 structure (center). For clarity, relevant residues in the A1-B1 loop are shown separately (right).
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DISCUSSION
Previous studies led to the solution of the NT-Als9-2 struc-
ture that revealed a PBC and proposed a novel mechanism for
the ability of Als proteins to bind a broad variety of protein
ligands (14). In the current work, we refined our knowledge of
NT-Als structure by extending crystallographic analysis toNT-
Als3. We used structurally informed mutagenesis to remove
essential contacts for ligand binding (NT-Als3-pbc) or to
exclude ligand entry into the PBC (NT-Als3-gk), without
affecting NT-Als3 surface structure. We also used amino acid
substitutions to eliminate the amyloidogenic potential of the
AFR region of the protein (NT-Als3-afr). Structural analysis of
these mutant proteins revealed previously unrecognized inter-
play between the PBC and AFR, in which ligand-binding status
of the PBC affects AFR placement relative to the NT-Als3 pro-
tein domains. These mutations were placed into the context of
full-length Als3 and displayed in their native context on the C.
albicans surface. Resulting strains were assayed in widely used
adhesion models and successfully dissected the effects of C.
albicans attachment to human cells (here defined as “adhe-
sion”), fromC. albicans intercellular interactions (here, defined
as cellular “aggregation”).
Adhesion, as evaluated in these standard models, likely is
often considered at face value, without contemplating themany
complex interactions that are reflected in the final data. In the
C. albicansAls literature, the adhesive phenotype is often eval-
uated using systems that involve protein overproduction in
nonnative settings. These approaches allow the study of an
individual adhesin away from the naturally sticky context of the
C. albicans cell. Amid these approaches, then, our results are
stunning: substitution of one or three amino acids is sufficient
to change C. albicans adhesive phenotype from wild-type to
that of aals3/als3 deletionmutant, while still presenting the
native surface of Als3 on the fungal cell. The ability of Als3 PBC
function to emerge so clearly from the complex interactions of
the adhesion assay is a testament to the importance ofAls3 inC.
albicans adhesion and the importance of the PBC in the adhe-
sion event.
Initial speculation about the Als ligand-binding mechanism
suggested that it occurs by interactions between the NT-Als
surface and the surface of the ligand (8, 16, 32). This idea
became more unlikely, however, as numerous Als ligands, par-
ticularly for Als3, were reported in the literature. Cell biology-
based inquiry has provided an extensive list of divergent bind-
ing partners for Als3 including human fibronectin, laminin,
collagen, gp96, EGFR, HER2, N-cadherin, E-cadherin, fibrino-
gen, casein, equine ferritin, bovine serum albumin, and Strep-
tococcus gordonii SspB (8, 9, 32–37). These reports raise the
question of how NT-Als3 can adapt to surfaces of so many
structurally unrelated ligands to establish biologically relevant
interactions. Solution of the NT-Als molecular structure and
discovery of the PBC (12) provided themeans to reconcile these
data into a model of Als protein structure and function that is
supported by experimental techniques able to provide informa-
tionwith atomic resolution. Thatmodel was further tested here
by site-directed mutagenesis of the PBC and accompanying
structural analyses demonstrating that the mutations do not
alter surface structure of the protein. Loss of adhesive function
for the Als3-pbc protein shows that Als3 binds free C termini of
host proteins and excludes the idea that Als3 interacts with
ligands using surface-surface interactions.
Experiments presented here provide the first data to address
function of the Als PBC. In contrast, function of the AFR has
been discussed extensively in the C. albicans literature and a
functional model proposed (16). This model features adhesive
contact between the NT domains of mature Als molecules and
a mechanical stimulus to stretch each Als molecule, causing
exposure of previously obscured amyloid-forming sequences. It
is proposed that interaction between these sequences leads to
amyloid nanodomain formation that induces strong adhesive
interactions. Some of our data are in agreementwith thismodel
whereas others suggest the need for modifications. Our results
demonstrate the principal role of the PBC in ligand binding and
recognition of cell surfaces and do not support a role for the
AFR, in a free or clustered state, to perform these functions.
Importantly, structural information shows that the AFR is
FIGURE 8.Proposed conformations of theAFR inAls adhesins.Newly synthesized Als3 in “free form” (center), is competent for ligand binding via the PBC or
for aggregationmediated by the AFR. As inferred fromGarcia et al. (30) and our NMR data (Fig. 2), interaction between the AFR of Als3 proteins on different C.
albicans cells leads to formation of aggregates (amyloid; right). Mutations in this region (e.g. V312N (30) or I311S/I313S (Fig. 2)) abolish this phenotype. In the
presence of ligands, the AFR attaches to the surface of the adhesin (left), as revealed by the crystal structure of the NT-Als9Fg- complex (14). High affinity
ligands are predicted to shift the equilibrium toward this nonaggregative protein-ligand complex. If aggregative interactions are disrupted bymutation of the
AFR, the PBC could becomemore available to bind ligands, as evidenced by the increased binding to human cell monolayers of the Als3-afr strain (Fig. 5).
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located at the boundary between the NT and the T-rich
domains, not in the T-rich domain as suggested previously (16).
This region is competent for amyloidogenic interactions in the
ligand-free form of the protein, but it is docked to the surface of
the adhesin in the ligand-bound form, meaning that ligand
binding (e.g. adhesion) and AFR-mediated amyloid formation
(involved in C. albicans aggregation) are mutually exclusive
processes (Fig. 8). These data also show that ligand binding by
the PBC is passive, i.e. does not require activation of Als
domains by mechanical/extension forces (16).
Nonetheless, our data demonstrating that germ tubes aggre-
gatewhen grownwith shaking, but not in static culture, support
the concept of Als protein force-activated aggregative interac-
tions. Similarly, our phenotypic data for Als3-afr in adhesion
assays suggest that the AFR mediates interactions between Als
proteins on the sameC. albicans cell or betweenAls proteins on
different C. albicans cells, consistent with the previous model.
Strains 1893 and 3464 encode the same ALS3 allele, yet can
differ significantly in their adhesion phenotype in an assay-spe-
cific manner (Fig. 5). The only apparent difference between
these strains is the abundance of Als3 cell surface protein, as
detected by immunofluorescent labelingwith an anti-Als3-spe-
cific monoclonal antibody. This demonstration of the effect of
protein abundance on adhesion assay conclusions raises new
questions regarding the pre-eminence of Als3 contribution to
C. albicans adhesion: does deletion of ALS3 cause the largest
decrease in C. albicans adhesion because Als3 is an adhesin
with the greatest affinity to ligands, or becauseAls3 is produced
in abundance across the greatest expanse of the C. albicans
germ tube? Other Als proteins are known to have a restricted
localization on theC. albicans germ tube (e.g.Als4 (38)) or to be
present at such low abundance that they cannot be visualized
using standard immunolabeling techniques (e.g. Als5, Als6 (26,
39)). Consequently, standard adhesion assays suggest little con-
tribution of these proteins toC. albicans phenotype. It is highly
likely that misexpression of ALS genes to increase their abun-
dance to native Als3 levels and/or alter the cell surface distri-
bution of the encoded proteins may result in different conclu-
sions regarding adhesive function of the various Als proteins.
The C. albicans strains described here provide the means to
dissect the effects of the PBC and AFR on more complex phe-
notypes important toC. albicanspathogenesis, such as invasion
and biofilm formation. Our suite of tools and approaches are
also poised to address questions regarding the relationship
between Als protein sequence, localization, and abundance to
C. albicans phenotype. These data will contribute additional
insight into the mechanism of Als protein function.
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